Adept adds two support staff

For expanding range of data acquisition products

Adept Scientific, based in Letchworth, Hertfordshire, UK, has taken on two new members of staff to support its expanding range of data acquisition products (DAQ).

Henrique da Silva will concentrate on DAQ sales. He has an MSc in Electronics & Computer Engineering.

Elizabeth Northrop (Lilly) will focus on technical support. She has an MEng in Systems Engineering.

With offices in the UK, Germany and throughout the Nordic region, Adept Scientific is a supplier of software and hardware products for research, scientific, engineering and technical applications on desktop computers.

You may also like

Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Digital

Why CGT manufacturers should automate the production process

Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space, personnel and cost efficient
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now